1-Diaethylamino-5,5-dimethyl-hexan | 2424-18-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Diaethylamino-5,5-dimethyl-hexan
• 英文别名: (5,5-Dimethyl-hexyl)-diethyl-amine；N,N-diethyl-5,5-dimethylhexan-1-amine
• CAS: 2424-18-2
• 化学式: C₁₂H₂₇N
• 分子量: 185.353
• InChiKey: LYKXUOXVKIEYPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Diaethylamino-5.5-dimethyl-hexen-(2) 在 Lindlar's catalyst 氢气 作用下， 以 甲醇 为溶剂， 生成 1-Diaethylamino-5,5-dimethyl-hexan
  参考文献：
  名称：

  Kolyaskina,Z.N.; Gi'ym,K., Journal of Organic Chemistry USSR (English Translation), 1965, vol. 1, # 4, p. 643 - 644

  摘要：

  DOI：

文献信息

• [EN] BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] DERIVES DE BENZAMIDE UTILES EN TANT QU'INHIBITEURS D'HISTONE DEACETYLASE
  申请人：ASTRAZENECA AB

  公开号：WO2003087057A1

  公开（公告）日：2003-10-23

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.

  本发明涉及一种公式(I)的化合物，其中环A是杂环；m为0-4，每个R1是如羟基、卤素、三氟甲基和腈的基团；R2是卤素，n为0-2；每个R4是如羟基、卤素、三氟甲基和腈的基团；p为0-4；R3是氨基或羟基；或其药物可接受的盐或体内可水解的酯或酰胺及其制备过程，包含它们的药物组合物以及它们在治疗由组蛋白脱乙酰酶介导的疾病或医疗条件中的用途。
• EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS
  申请人：Martinez-Perez Jose Antonio

  公开号：US20100094014A1

  公开（公告）日：2010-04-15

  The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).

  本发明提供了公式（I）和公式（I（a））的新化合物，或其药学上可接受的盐；治疗神经系统疾病和神经退行性疾病的方法，特别是治疗疼痛和偏头痛，包括给予公式（I）或公式（I（a））的化合物；以及制备公式（I）或公式（I（a））化合物的过程。
• Thiophene and furan compounds
  申请人：Castano Mansanet Maria Ana

  公开号：US20070105852A1

  公开（公告）日：2007-05-10

  The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.

  本发明涉及噻吩和呋喃化合物及其药学上可接受的盐，并进一步涉及它们在治疗精神分裂症、与精神分裂症相关的认知缺陷、阿尔茨海默病、阿尔茨海默型痴呆、轻度认知障碍或抑郁症中的应用。
• BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS
  申请人：Stokes Elaine Sophie Elizabeth

  公开号：US20090029991A1

  公开（公告）日：2009-01-29

  The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R 1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R 2 is halo and n is 0-2; and each R 4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R 3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by histone deacetylase.

  本发明涉及式（I）的化合物，其中环A是杂环基；m为0-4，每个R1是羟基、卤素、三氟甲基和氰基等基团；R2是卤素，n为0-2；每个R4是羟基、卤素、三氟甲基和氰基等基团；p为0-4；R3是氨基或羟基；或其药学上可接受的盐或体内可水解的酯或酰胺，其制备方法，含有它们的制药组合物以及它们在通过组蛋白去乙酰化酶介导的疾病或医学情况的治疗中的应用。
• Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
  申请人：Albaugh Ann Pamela

  公开号：US20070066573A1

  公开（公告）日：2007-03-22

  The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.

  本发明涉及式(I)的吡咯和吡唑化合物及其药学上可接受的盐，并进一步涉及它们在治疗精神分裂症、与精神分裂症相关的认知缺陷、阿尔茨海默病、阿尔茨海默型痴呆、轻度认知障碍或抑郁症方面的使用。这些化合物在谷氨酸受体上发挥增强剂作用，特别是AMPA和GluR家族。